Ocuphire Pharma, Inc. — Q1 2021 Form 10-Q
Filing identity: The supplied filing is for Ocuphire Pharma, Inc. (Nasdaq: OCUP), not Opus Genetics, Inc. It covers the unaudited quarter ended March 31, 2021; comparative results are for the three months ended March 31, 2020.
Business context
Ocuphire is a clinical-stage ophthalmic biopharmaceutical company with no approved products and no revenue. Its pipeline includes Nyxol eye drops, APX3330, and the in-licensed candidates APX2009 and APX2014. The company expects to rely on external financing until any product candidates are approved and commercialized.
Financial performance and liquidity
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | None | None |
| Operating expenses | $5.2 million | $2.7 million |
| Operating loss | $5.2 million | $2.7 million |
| Net loss | $39.0 million | $3.1 million |
| Cash used in operating activities | $5.8 million | $0.7 million |
At March 31, 2021, cash and cash equivalents were $10.6 million, total current assets $12.1 million, and current liabilities $2.3 million. The company reported no debt outstanding; its convertible notes had converted to equity in November 2020. No meaningful revenue margins are available because the company has not generated revenue.
The $39.0 million quarterly net loss included a $33.8 million non-cash expense from changes in fair value of warrant liabilities and related derivatives. Operating cash burn was therefore substantially lower than reported net loss. The Series A warrants were reclassified from liabilities to equity in February 2021, after waiver agreements eliminated certain anti-dilution terms; the warrants are no longer remeasured.
Material changes versus the prior comparable period
- Research and development expense increased to $3.5 million from $0.2 million, primarily reflecting four new clinical trials and Nyxol and APX3330 manufacturing, regulatory, and development work.
- General and administrative expense rose to $1.7 million from $0.4 million, largely due to added personnel, stock compensation, insurance, professional services, and public-company costs.
- The prior-year quarter included $2.1 million of acquired in-process R&D expense related to the Apexian sublicense and $0.6 million of convertible-note interest expense; neither was recorded in Q1 2021.
- Cash decreased by $5.8 million during the quarter, from $16.4 million at year-end 2020. Stockholders’ equity was $9.8 million at March 31, compared with a $13.5 million deficit at December 31, 2020, principally reflecting the warrant reclassification to equity.
Outlook, risks, and unusual items
- Funding and going concern: Management said existing cash would not fund operating expenses and capital requirements for the next 12 months from the filing date. The filing identifies substantial doubt about the company’s ability to continue as a going concern and says additional financing is needed, with no assurance it can be obtained. Failure to raise funds could delay, reduce, or end development programs.
- Clinical outlook: After positive top-line results from Nyxol’s MIRA-2 Phase 3 trial in March 2021, management planned to begin the second registration trial, MIRA-3, in the second half of 2021, with results expected in early 2022. If the reversal-of-mydriasis trials succeed and proceed on schedule, the company anticipated filing a Nyxol NDA in early 2023. Further readouts from other Nyxol studies were expected during 2021. APX3330’s diabetic-retinopathy Phase 2 trial began enrollment in April 2021, with top-line data expected by early 2022. These are expectations, not assurances.
- Financing and dilution: A $125 million shelf registration and a $40 million at-the-market program were available; no ATM shares were sold in Q1. Series A and B warrants covered 5.67 million and 1.71 million shares, respectively, before subsequent exercises, creating potential dilution.
- Subsequent events: In April, investors exercised Series B warrants for 1,629,634 shares for total proceeds of $163. On May 6, the company issued 350,000 shares to three investors under a settlement agreement in exchange for a release of potential claims.
- Other risks and contingencies: COVID-19 had disrupted supply, R&D, clinical recruitment and retention, regulatory processes, and financing efforts; management said continued effects could materially harm operations, financial position, and liquidity. The Apexian sublicense includes up to $11 million in development and regulatory milestones, up to $20 million in sales milestones, and single-digit royalties; none had been triggered by March 31, 2021. The company reported no material ongoing legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether the company obtained financing after the filing and whether its cash runway supports planned trials.
- Clinical-trial progress, enrollment, safety and efficacy results, and the timing of Nyxol and APX3330 readouts and regulatory milestones.
- The actual share count and potential dilution from outstanding warrants, options, ATM sales, and the 350,000-share settlement issuance.
- The magnitude and timing of future R&D spending, and whether COVID-19 or supply-chain disruptions affect development plans.
- The filing’s reported issuer is Ocuphire Pharma, Inc.; confirm that this is the intended company before relying on the figures.